These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31778672)

  • 1. Pharmacological rewriting of fear memories: A beacon for post-traumatic stress disorder.
    Uniyal A; Singh R; Akhtar A; Dhaliwal J; Kuhad A; Sah SP
    Eur J Pharmacol; 2020 Mar; 870():172824. PubMed ID: 31778672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconsolidation/destabilization, extinction and forgetting of fear memory as therapeutic targets for PTSD.
    Kida S
    Psychopharmacology (Berl); 2019 Jan; 236(1):49-57. PubMed ID: 30374892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of posttraumatic stress disorder and extinction learning of traumatic memory].
    Asukai N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Jun; 33(3):111-5. PubMed ID: 25069244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms of reconsolidation and extinction of fear memory].
    Kida S; Fukushima H; Mamiya N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Jun; 29(3):125-33. PubMed ID: 19663263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine accelerates fear extinction via mTORC1 signaling.
    Girgenti MJ; Ghosal S; LoPresto D; Taylor JR; Duman RS
    Neurobiol Dis; 2017 Apr; 100():1-8. PubMed ID: 28043916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A novel therapeutic approach for the treatment of post-traumatic stress disorder (PTSD): enhancing the impaired extinction of fear memory].
    Yamamoto S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Jun; 29(3):135-9. PubMed ID: 19663264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updating versus Exposure to Prevent Consolidation of Conditioned Fear.
    Pile V; Barnhofer T; Wild J
    PLoS One; 2015; 10(4):e0122971. PubMed ID: 25902141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of early stress on memory reconsolidation: Implications for post-traumatic stress disorder treatment.
    Villain H; Benkahoul A; Birmes P; Ferry B; Roullet P
    PLoS One; 2018; 13(1):e0191563. PubMed ID: 29352277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding posttraumatic stress disorder through fear conditioning, extinction and reconsolidation.
    Careaga MBL; Girardi CEN; Suchecki D
    Neurosci Biobehav Rev; 2016 Dec; 71():48-57. PubMed ID: 27590828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-treatment of piracetam with risperidone rescued extinction deficits in experimental paradigms of post-traumatic stress disorder by restoring the physiological alterations in cortex and hippocampus.
    Uniyal A; Singh R; Akhtar A; Bansal Y; Kuhad A; Sah SP
    Pharmacol Biochem Behav; 2019 Oct; 185():172763. PubMed ID: 31445955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy in the aftermath of trauma; opportunities in the 'golden hours'.
    Vermetten E; Zhohar J; Krugers HJ
    Curr Psychiatry Rep; 2014 Jul; 16(7):455. PubMed ID: 24890991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic mechanisms in fear conditioning: implications for treating post-traumatic stress disorder.
    Kwapis JL; Wood MA
    Trends Neurosci; 2014 Dec; 37(12):706-20. PubMed ID: 25220045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The downside of strong emotional memories: how human memory-related genes influence the risk for posttraumatic stress disorder--a selective review.
    Wilker S; Elbert T; Kolassa IT
    Neurobiol Learn Mem; 2014 Jul; 112():75-86. PubMed ID: 24012801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTSD-like memory generated through enhanced noradrenergic activity is mitigated by a dual step pharmacological intervention targeting its reconsolidation.
    Gazarini L; Stern CA; Piornedo RR; Takahashi RN; Bertoglio LJ
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid-induced enhancement of extinction-from animal models to clinical trials.
    de Quervain D; Wolf OT; Roozendaal B
    Psychopharmacology (Berl); 2019 Jan; 236(1):183-199. PubMed ID: 30610352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies.
    Lisboa SF; Vila-Verde C; Rosa J; Uliana DL; Stern CAJ; Bertoglio LJ; Resstel LB; Guimaraes FS
    Psychopharmacology (Berl); 2019 Jan; 236(1):201-226. PubMed ID: 30604182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting neuronal nitric oxide synthase and the nitrergic system in post-traumatic stress disorder.
    Sadeghi MA; Hemmati S; Nassireslami E; Yousefi Zoshk M; Hosseini Y; Abbasian K; Chamanara M
    Psychopharmacology (Berl); 2022 Oct; 239(10):3057-3082. PubMed ID: 36029333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting memory processes with drugs to prevent or cure PTSD.
    Cain CK; Maynard GD; Kehne JH
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1323-50. PubMed ID: 22834476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential roles of the infralimbic and prelimbic areas of the prefrontal cortex in reconsolidation of a traumatic memory.
    Levin N; Kritman M; Maroun M; Akirav I
    Eur Neuropsychopharmacol; 2017 Sep; 27(9):900-912. PubMed ID: 28647452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder.
    Barreto GE; Yarkov A; Avila-Rodriguez M; Aliev G; Echeverria V
    Curr Pharm Des; 2015; 21(25):3589-95. PubMed ID: 26166610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.